DALLAS, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced results from studies demonstrating the ability of UB-612, its COVID-19 vaccine candidate, to elicit a broad immune response against multiple variants of concern, and specifically more than three-times higher titers of neutralizing antibodies against the Omicron variant of SARS-CoV-2 than an approved mRNA vaccine with boosters.
Read more at globenewswire.comVaxxinity’s COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Other Variants of Concern
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Apple%20Inc%20logo%20on%20Apple%20store-by%20PhillDanze%20via%20iStock.jpg)
/Elon%20Musk%2C%20founder%2C%20CEO%2C%20and%20chief%20engineer%20of%20SpaceX%2C%20CEO%20of%20Tesla%20by%20Frederic%20Legrand%20-%20COMEO%20via%20Shutterstock.jpg)